# ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial

> **NCT00752986** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 39 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** ZD6474 (Vandetanib at the dose of 100 mg)
- **DRUG:** Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)
- **DRUG:** Fulvestrant
- **DRUG:** ZD6474 (Vandetanib at the dose of 300 mg)
- **DRUG:** Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)

## Key facts

- **NCT ID:** NCT00752986
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-12
- **Primary completion:** 2013-09
- **Final completion:** 2013-09
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00752986

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00752986, "ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00752986. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*